The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
about
The phage lytic proteins from the Staphylococcus aureus bacteriophage vB_SauS-phiIPLA88 display multiple active catalytic domains and do not trigger staphylococcal resistanceA Carrier Protein Strategy Yields the Structure of DalbavancinHost immune transcriptional profiles reflect the variability in clinical disease manifestations in patients with Staphylococcus aureus infectionsEfficacy of ampicillin against methicillin-resistant Staphylococcus aureus restored through synergy with branched poly(ethylenimine)Functional characterization of TcaA: minimal requirement for teicoplanin susceptibility and role in Caenorhabditis elegans virulenceHigh precision multi-genome scale reannotation of enzyme function by EFICAz.Does vancomycin prescribing intervention affect vancomycin-resistant enterococcus infection and colonization in hospitals? A systematic reviewDifferent bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia.Imcroporin, a new cationic antimicrobial peptide from the venom of the scorpion Isometrus maculates.Telavancin for hospital-acquired pneumonia: clinical response and 28-day survivalMyricetin protects Galleria mellonella against Staphylococcus aureus infection and inhibits multiple virulence factors.A novel STK1-targeted small-molecule as an "antibiotic resistance breaker" against multidrug-resistant Staphylococcus aureus.The C-terminal domain of the novel essential protein Gcp is critical for interaction with another essential protein YeaZ of Staphylococcus aureusMethicillin and Vancomycin Resistant S. aureus in Hospitalized Patients.Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.The essentiality of staphylococcal Gcp is independent of its repression of branched-chain amino acids biosynthesis.Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational studyNadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771.Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing.In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.Vancomycin tolerant, methicillin-resistant Staphylococcus aureus reveals the effects of vancomycin on cell wall thickeningCtriporin, a new anti-methicillin-resistant Staphylococcus aureus peptide from the venom of the scorpion Chaerilus tricostatusIn vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.Glycopeptide resistance in gram-positive cocci: a review.Determination of essentiality and regulatory function of staphylococcal YeaZ in branched-chain amino acid biosynthesis.Isolation and Genome Characterization of the Virulent Staphylococcus aureus Bacteriophage SA97.The Ethical Significance of Antimicrobial Resistance.Lubricin: a novel means to decrease bacterial adhesion and proliferationPrevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients.Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.Mucroporin, the first cationic host defense peptide from the venom of Lychas mucronatusExpanding role of lipid II as a target for lantibiotics.Monoclonal antibodies for prophylaxis and therapy of infectious diseases.Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Ideal microbiological and pharmacological characteristics of a quality antimicrobial agent: comparing original and generic molecules.Antimicrobial resistance in hospitals: how concerned should we be?Molecular epidemiology of clinically significant antibiotic resistance genes.Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.In Vitro and In Vivo Synergy of the Oxadiazole Class of Antibacterials with β-Lactams.
P2860
Q21089782-8E4968AC-FE56-4108-B8E3-5317816248C4Q27677393-FF16CDA1-FAA1-4AEA-A5E2-0E837BABDF30Q28730753-DB2178A9-FAB9-4FC1-8A49-7F5C27B6BCFBQ28821040-04BA331C-5B5E-46BC-AF54-3D0E4E4348DCQ30443507-013B467E-8559-4429-AF6B-FB12D0BFE1A8Q33266468-775EACE5-BC4D-46A7-A642-71804FE2D5C6Q33281709-95C5BEB9-3C36-4621-AFBB-A42A0299B5C0Q33321447-146F9773-D8CA-4FD8-B4F9-00658E007365Q33447111-DAE06271-B3E5-4C19-95CC-462E2C78EA5EQ33622851-05C798E5-593F-49C6-8530-8C828F7A2D65Q33767539-496CB331-B5FA-4DD2-B8CF-C340D0AF03D9Q33894853-683EBB10-FFF7-44E8-B78A-83AD83FFD588Q33916407-65E72CDB-B170-4E2C-A146-7A3B32FDC236Q34142160-1A7DF5D8-A966-482E-A8F5-3738CA4135E6Q34309620-AF929521-34CB-4553-8116-F7B88FA93358Q34442251-9FD3781E-8832-4985-A077-8892D6B020D4Q34486095-B05843CB-E569-4E9C-B23E-91C2C55768CDQ34571545-6AC6318D-A2A4-4A47-A2DD-83002230694EQ34630593-709EDF70-F76D-4529-A1E6-923EEC1AD4FEQ35005092-55929E6B-607C-42BF-A1D1-5D56E52B584CQ35203343-136A0173-A314-4B55-8D7D-92EA223F46A2Q35364564-0144B5AC-5FA7-446C-B2F2-2C7635BDC50FQ35758882-7349FBCD-FD5B-4C0F-BD67-0BFCE0F4F4A5Q36072225-74B4C89C-6307-46A3-AB73-5CD928FFF00EQ36154997-F9279906-750B-4645-ABC4-0649C148AD57Q36246630-A73BF99E-E815-468C-A1FC-E31FF60B58EEQ36263119-EEF1296E-DCEF-4409-B07A-E5F7E20B6607Q36347648-207D1671-0A87-426A-93E7-5D38909AB83DQ36636699-A818F9AA-187D-4993-ACBF-F71997C1CBB4Q36771148-45F7BF6B-0427-4E0E-9873-86675360512BQ36949473-2B08FBE7-ADC6-4023-8023-02892919DC35Q36967247-27A50DF2-BE04-4350-A85F-5BD1E10DB6CFQ36989900-3E3E69B2-9AA0-45CB-907A-25F4CC47C850Q37071199-C69A3B08-0E11-43F9-9D0E-C4739CE1D35BQ37071315-51166562-D118-4357-9827-2368ABEF3B27Q37088893-F9692BC7-E54A-45AB-A3E1-B2FB61D761A3Q37098582-08FF509C-163B-4892-9280-863FBB1A6433Q37174100-88EEE731-2C49-4DD1-8BB0-A09992A8E4CFQ37190843-FA21D033-1F01-4F4A-97C5-689C24DEE875Q37203885-FD31758E-3EEB-4FBC-A364-B63CACC9C6E6
P2860
The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
@ast
The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
@en
type
label
The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
@ast
The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
@en
prefLabel
The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
@ast
The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
@en
P1476
The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
@en
P2093
Appelbaum PC
P356
10.1111/J.1469-0691.2006.01344.X
P478
12 Suppl 1
P577
2006-03-01T00:00:00Z